Archives

by in
Entry Author Date Location
West Coast Biotech Roundup: Amgen Layoffs, Avalanche, Venter & More 07/31/14 Seattle
West Coast Biotech Roundup: IPOs, Gilead, Sofinnova, & Denouements 07/25/14 San Diego
BioCryst Bets on New Ebola Drug to Fight Bioterror, Outbreak Threats 07/24/14 Raleigh Durham
Gilead Edges Into Cancer Field With FDA OK of Calistoga Drug 07/23/14 San Francisco
Who Needs Biotech VCs, Anyway? 07/15/14 San Francisco
West Coast Biotech Roundup: Scripps, Trounson, Versant, Gilead, & More 07/10/14 San Francisco
King of BIO: The Chairwoman of Biotech’s Top Trade Org Talks Policy 06/25/14 San Diego
SF Biotech Venture Vet Steve Burrill Dumped by LPs, Sued for Fraud 06/18/14 San Francisco
Merck Scoops Up Idenix in $3.85B Buyout 06/09/14 Boston
Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race 06/09/14 Boston
Promedior Sees Hope in Small Myelofibrosis Study 05/30/14 Boston
What Price Technology? At NYT Health Confab, It’s a Loaded Question 05/30/14 San Francisco
GlobeImmune Cuts Size of Pending IPO by 29 Percent 05/22/14 Boulder/Denver
East Coast Biotech Roundup: Neurophage, Boston Biotech, Insmed, & More 03/28/14 Boston
Seattle BioMed Nabs $10M NIAID Grant to Develop HIV Vaccines 03/10/14 Seattle
Elliott Sigal, Bristol’s Former R&D Chief, on Life After Big Pharma 02/25/14 New York
San Diego Life Sciences Roundup: Shire, Illumina, Tandem, and More 01/24/14 San Diego
Enanta, No Longer Obscure, Seeks Slice of Big Hepatitis C Market 01/24/14 Boston
The Big Guys Have Lost Their Iron Grip, and It’s All Good 01/20/14 National
Alkermes Nabs $250M It Doesn’t Need, But Could Fend Off Barbarians 01/13/14 Boston
What Biotech Pros Will Be Chirping About at JP Morgan This Week 01/13/14 National
Tillman Gerngross, the Scientist Turned Scientific Businessman 01/09/14 Boston
Gilead Wins FDA Approval for Big Hepatitis C Drug 12/06/13 San Francisco
San Diego Life Sciences Roundup: Ignyta, Conatus, Liver Prize & More 12/06/13 San Diego
3 Life Sciences Companies That Are Built to Last 12/02/13 National
Armo BioSciences Joins the Cancer Immunotherapy Party With $20M 11/25/13 San Francisco
Vertex Sells Hep C Drug Royalty Rights to Janssen for $152M 11/20/13 Boston
How Alkermes Survived a Brush With Death 11/11/13 National
Vertex Cuts 15% of Workforce as Hepatitis C Drug Sales Drop 10/29/13 Boston
The Biggest Bargains Pharma Scooped Up in the Down Years 10/28/13 National
Page 1 of 6 next page »